New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
18:54 EDTUTX, PAY, SZYM, CYTX, ZQK, ADBE, NIHD, NUVAOn The Fly: After Hours Movers
UP AFTER EARNINGS: Adobe (ADBE), up 6%... ALSO HIGHER: Solazyme (SZYM), up 10% after filing a $30M mixed securities shelf... NuVasive (NUVA), up 3% after releasing $62.5M from escrow following court ruling... DOWN AFTER EARNINGS: Quicksilver (ZQK), down 16%... VeriFone Systems (PAY), down 6%... ALSO LOWER: NII Holdings (NIHD), down 6% after naming an interim CEO... Cytori Therapeutics (CYTX), down 12% after proposing a common stock offering... United Technologies (UTX), down 1% after providing FY12, FY13 EPS guidance.
News For ADBE;SZYM;NUVA;ZQK;PAY;NIHD;CYTX;UTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
18:10 EDTUTXLockheed Martin, United Technologies JV awarded $2B government contract
Subscribe for More Information
February 26, 2015
16:23 EDTSZYMSolazyme reports Q4 EPS (57c), consensus (47c)
Reports Q4 revenue $14.5M, consensus $17.7M.
12:15 EDTNUVANuVasive management to meet with Piper Jaffray
Meetings to be held in New York on March 3 and in Denver on March 4 hosted by Piper Jaffray.
08:02 EDTCYTXCytori Therapeutics says receives FDA approval to expand Scleroderma trial
Cytori Therapeutics announced that it received approval from FDA to expand the number of Scleroderma clinical trial sites from 12 to 20 centers in the United States. The STAR study is an 80 patient pivotal clinical trial approved by FDA in January to study the effects of Cytori’s lead drug ECCS-50 for treatment of patients with hand manifestations of Scleroderma.
February 25, 2015
17:23 EDTUTXUnited Technologies awarded $407M government contract
United Technologies Corp., East Hartford, Connecticut, has been awarded a $407M indefinite-delivery/indefinite-quantity contract for engine component improvement program. Contractor will provide design improvement, life management/analysis, repair development and test of engines produced by Pratt & Whitney. Work will be performed at East Hartford, Connecticut, and is expected to be complete by Dec. 31, 2021. This contract involves foreign military sales. This award is the result of a sole-source acquisition. Fiscal year 2015 research, development, test and evaluation funds in the amount of $5M are being obligated at the time of award for task order 0001. Air Force Life Cycle Management Center, Wright-Patterson Air Force Base, Ohio, is the contracting activity.
07:09 EDTUTXUnited Technologies price target to $138 ahead of Analyst Day at Credit Suisse
Subscribe for More Information
05:11 EDTSZYMSolazyme receives FDA GRAS No Questions Letter for high oleic algae oil
Solazyme announced that the FDA has issued a favorable response to Solazyme’s notification which concludes that high-oleic algae oil is Generally Recognized as Safe as an ingredient in food products under the intended conditions of use. This No Questions letter will further pave the way for mainstream adoption of superior quality oleic algae oil with unprecedented functional, performance and nutritional benefits, enabling the creation of new products that meet consumer demand for healthy, sustainable ingredients. Solazyme has also received FDA No Questions letters for the whole food ingredient products currently offered within the AlgaVia portfolio, including Whole Algal Protein and Whole Algal Flour.
February 24, 2015
16:30 EDTNUVANuVasive announces updated Non-GAAP definition
NuVasive announced that it will implement an updated non-GAAP definition in Q1. NuVasive will redefine its non-GAAP cost of goods sold, gross margin, operating expenses, operating margin and earnings per share financial measures from its existing non-GAAP definition to include the impact of non-cash stock-based compensation and certain intellectual property related litigation expenses, both of which had previously been excluded in the company's calculation of these non-GAAP financial measures. In addition to GAAP results, these non-GAAP measures are intended to provide additional information to enable investors to assess the Company's operations in the same way management assesses operations. Management uses non-GAAP measures to budget, evaluate and measure the company's performance and sees these results as an indicator of the company's ongoing business performance. The company believes these changes in non-GAAP reporting increase transparency and better reflect the underlying financial performance of the business. CFO Quentin Blackford said, "This update allows us to provide investors with a meaningful non-GAAP measurement that represents the performance of our core business on a more inclusive, comprehensive basis. Importantly, this change does not impact NuVasive's plan to deliver at least 100 basis points of operating margin expansion each year, as well as improved EBITDA margins for the next several years as we rapidly scale the business in the U.S. and internationally and capture well-identified opportunities to drive profitability."
16:18 EDTNUVANuVasive sees FY15 adjusted EPS approximately $1.10, consensus $1.53
Sees FY15 revenue approximately $810M, consensus $811.03M, which includes an approximate $10M of currency headwinds.
16:16 EDTNUVANuVasive reports Q4 adjusted EPS 39c, consensus 37c
Reports Q4 revenue $204.3M, consensus $201.39M.
08:17 EDTCYTXCytori Therapeutics receives positive European opinion on orphan drug status
Subscribe for More Information
February 23, 2015
08:00 EDTADBEAdobe shares recommended at Rosenblatt
Rosenblatt believes Adobe continues to execute and will report Q1 earnings and revenues slightly ahead of consensus estimates of 40c/1.09B and for new sub adds and Marketing Cloud billing to be above expectations.
06:51 EDTUTXAerospace sector downgraded to Neutral from Attractive at Goldman
Goldman downgraded the Aerospace sector to Neutral based on group outperformance and increased downside risks. The firm believes Boeing (BA) and Airbus are now oversupplying the market after a decade of undersupply and replacement demand required to sustain production may prove difficult to achieve. Goldman said accelerated new aircraft replacements was partially due to fuel economics and lower fuel prices and global growth volatility could substantially change Aerospace dynamics. As part of the sector view change, Goldman downgraded Boeing to Sell from Neutral and Precision Castparts (PCP) to Natural from Buy.
February 20, 2015
06:27 EDTUTXUnited Tech's Sikorsky may look to make military helicopters in India, WSJ says
Subscribe for More Information
February 17, 2015
08:03 EDTCYTXCytori Therapeutics begins enrollment in Phase II ACT-OA trial
Cytori Therapeutics announced that the first patient has been treated in its FDA approved trial assessing the effect of Cytori Cell Therapy for osteoarthritis of the knee. The patient was treated by Dr. Peter Hanson, Medical Director of Orthopedic Surgery at Sharp Grossmont Hospital. ACT-OA is a Phase II FDA approved randomized, double-blind, placebo controlled trial in 90 patients evaluating the efficacy and safety of Cytori’s autologous adipose derived therapy ECCO-50 (Cytori’s therapeutic under study). The trial tests both a low dose and a high dose vs. placebo and will be conducted over 48 weeks. The randomization will be 1:1:1 between the control, low dose and high dose groups. The primary end point will be pain on walking as measured by the Knee Injury and Osteoarthritis Outcome Score at 12 weeks. Secondary endpoints assessed will include pain, joint function, magnetic resonance imaging and adverse events.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use